Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment

Immunity

Volumn 51, Issue 2, 2019, Pages 367-380.e4

  Eftychi, Christina ^a   Schwarzer, Robin ^a   Vlantis, Katerina ^a   Wachsmuth, Laurens ^a   Basic, Marijana ^b   Wagle, Prerana ^a   Neurath, Markus F ^c   Becker, Christoph ^c   Bleich, André ^b   Pasparakis, Manolis ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

altered Schaedler flora; dysbiosis; IFN ; IL 12; IL 23; inflammatory bowel disease; intestinal barrier impairment; intestinal inflammation; microbiota; MyD88

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN P40; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BONE MARROW CELL; CELL DIFFERENTIATION; CELL INFILTRATION; CHRONIC DISEASE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; COLITIS; COLON FLORA; CONTROLLED STUDY; EPITHELIUM HYPERPLASIA; GENE EXPRESSION; IMMUNE RECONSTITUTION; IMMUNOCOMPETENT CELL; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH17 CELL; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; KNOCKOUT MOUSE; METABOLISM; MICROFLORA; PATHOLOGY;

ANIMALS; CHRONIC DISEASE; COLITIS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-23; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROBIOTA; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; TRANSPLANTATION CHIMERA;

EID: 85070659354     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2019.06.008     Document Type: Article

References (61)

1. Ahern, P.P., Schiering, C., Buonocore, S., McGeachy, M.J., Cua, D.J., Maloy, K.J., Powrie, F., Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity 33 (2010), 279–288.
2. Becker, C., Dornhoff, H., Neufert, C., Fantini, M.C., Wirtz, S., Huebner, S., Nikolaev, A., Lehr, H.A., Murphy, A.J., Valenzuela, D.M., et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J. Immunol. 177 (2006), 2760–2764.
3. Becker, C., Neurath, M.F., Wirtz, S., The intestinal microbiota in inflammatory bowel disease. ILAR J. 56 (2015), 192–204.
4. Ben-Horin, S., Kopylov, U., Chowers, Y., Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun. Rev. 13 (2014), 24–30.
5. Bouma, G., Strober, W., The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3 (2003), 521–533.
6. Buhner, S., Buning, C., Genschel, J., Kling, K., Herrmann, D., Dignass, A., Kuechler, I., Krueger, S., Schmidt, H.H., Lochs, H., Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?. Gut 55 (2006), 342–347.
7. Chow, J., Tang, H., Mazmanian, S.K., Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr. Opin. Immunol. 23 (2011), 473–480.
8. Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., Förster, I., Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8 (1999), 265–277.
9. Cox, J.H., Kljavin, N.M., Ota, N., Leonard, J., Roose-Girma, M., Diehl, L., Ouyang, W., Ghilardi, N., Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol. 5 (2012), 99–109.
10. Davidson, N.J., Hudak, S.A., Lesley, R.E., Menon, S., Leach, M.W., Rennick, D.M., IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J. Immunol. 161 (1998), 3143–3149.
11. Eberl, G., Marmon, S., Sunshine, M.J., Rennert, P.D., Choi, Y., Littman, D.R., An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat. Immunol. 5 (2004), 64–73.
12. Edgar, R., Domrachev, M., Lash, A.E., Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30 (2002), 207–210.
13. el Marjou, F., Janssen, K.P., Chang, B.H., Li, M., Hindie, V., Chan, L., Louvard, D., Chambon, P., Metzger, D., Robine, S., Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39 (2004), 186–193.
14. Feagan, B.G., Sandborn, W.J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J.R., Blank, M.A., Johanns, J., Gao, L.L., Miao, Y., et al., UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 375 (2016), 1946–1960.
15. Feagan, B.G., Sandborn, W.J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389 (2017), 1699–1709.
16. Furfaro, F., Gilardi, D., Allocca, M., Cicerone, C., Correale, C., Fiorino, G., Danese, S., IL-23 Blockade for Crohn's disease: next generation of anti-cytokine therapy. Expert Rev. Clin. Immunol. 13 (2017), 457–467.
17. Hollander, D., Vadheim, C.M., Brettholz, E., Petersen, G.M., Delahunty, T., Rotter, J.I., Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann. Intern. Med. 105 (1986), 883–885.
18. Hue, S., Ahern, P., Buonocore, S., Kullberg, M.C., Cua, D.J., McKenzie, B.S., Powrie, F., Maloy, K.J., Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203 (2006), 2473–2483.
19. Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., Cua, D.J., Littman, D.R., The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126 (2006), 1121–1133.
20. Kaplan, G.G., The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12 (2015), 720–727.
21. Kaser, A., Zeissig, S., Blumberg, R.S., Inflammatory bowel disease. Annu. Rev. Immunol. 28 (2010), 573–621.
22. Kastelein, R.A., Hunter, C.A., Cua, D.J., Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25 (2007), 221–242.
23. Katz, K.D., Hollander, D., Vadheim, C.M., McElree, C., Delahunty, T., Dadufalza, V.D., Krugliak, P., Rotter, J.I., Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 97 (1989), 927–931.
24. Kawasaki, T., Kawai, T., Toll-like receptor signaling pathways. Front. Immunol., 5, 2014, 461.
25. Khor, B., Gardet, A., Xavier, R.J., Genetics and pathogenesis of inflammatory bowel disease. Nature 474 (2011), 307–317.
26. Kiesslich, R., Duckworth, C.A., Moussata, D., Gloeckner, A., Lim, L.G., Goetz, M., Pritchard, D.M., Galle, P.R., Neurath, M.F., Watson, A.J., Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 61 (2012), 1146–1153.
27. Kugathasan, S., Saubermann, L.J., Smith, L., Kou, D., Itoh, J., Binion, D.G., Levine, A.D., Blumberg, R.S., Fiocchi, C., Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 56 (2007), 1696–1705.
28. Kullberg, M.C., Jankovic, D., Feng, C.G., Hue, S., Gorelick, P.L., McKenzie, B.S., Cua, D.J., Powrie, F., Cheever, A.W., Maloy, K.J., Sher, A., IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203 (2006), 2485–2494.
29. Lee, Y.K., Turner, H., Maynard, C.L., Oliver, J.R., Chen, D., Elson, C.O., Weaver, C.T., Late developmental plasticity in the T helper 17 lineage. Immunity 30 (2009), 92–107.
30. Lee, J.S., Tato, C.M., Joyce-Shaikh, B., Gulen, M.F., Cayatte, C., Chen, Y., Blumenschein, W.M., Judo, M., Ayanoglu, G., McClanahan, T.K., et al. Interleukin-23-Independent IL-17 production regulates intestinal epithelial permeability. Immunity 43 (2015), 727–738.
31. Liu, Z., Geboes, K., Heremans, H., Overbergh, L., Mathieu, C., Rutgeerts, P., Ceuppens, J.L., Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis. Eur. J. Immunol. 31 (2001), 1550–1560.
32. Madison, B.B., Dunbar, L., Qiao, X.T., Braunstein, K., Braunstein, E., Gumucio, D.L., Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J. Biol. Chem. 277 (2002), 33275–33283.
33. Magram, J., Connaughton, S.E., Warrier, R.R., Carvajal, D.M., Wu, C.Y., Ferrante, J., Stewart, C., Sarmiento, U., Faherty, D.A., Gately, M.K., IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 4 (1996), 471–481.
34. Mattner, F., Magram, J., Ferrante, J., Launois, P., Di Padova, K., Behin, R., Gately, M.K., Louis, J.A., Alber, G., Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26 (1996), 1553–1559.
35. Mombaerts, P., Iacomini, J., Johnson, R.S., Herrup, K., Tonegawa, S., Papaioannou, V.E., RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68 (1992), 869–877.
36. Moschen, A.R., Tilg, H., Raine, T., IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat. Rev. Gastroenterol. Hepatol. 16 (2018), 185–196.
37. Nenci, A., Becker, C., Wullaert, A., Gareus, R., van Loo, G., Danese, S., Huth, M., Nikolaev, A., Neufert, C., Madison, B., et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446 (2007), 557–561.
38. Neurath, M., Current and emerging therapeutic targets for IBD. Nat. Rev. Gastroenterol. Hepatol., 14, 2017, 688.
39. Neurath, M.F., Fuss, I., Kelsall, B.L., Stüber, E., Strober, W., Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182 (1995), 1281–1290.
40. Oppmann, B., Lesley, R., Blom, B., Timans, J.C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000), 715–725.
41. Round, J.L., Mazmanian, S.K., The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9 (2009), 313–323.
42. Sands, B.E., Chen, J., Feagan, B.G., Penney, M., Rees, W.A., Danese, S., Higgins, P.D.R., Newbold, P., Faggioni, R., Patra, K., et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study. Gastroenterology 153 (2017), 77–86.
43. Schmidt-Supprian, M., Bloch, W., Courtois, G., Addicks, K., Israël, A., Rajewsky, K., Pasparakis, M., NEMO/IKK γ-deficient mice model incontinentia pigmenti. Mol. Cell 5 (2000), 981–992.
44. Schwenk, F., Baron, U., Rajewsky, K., A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 23 (1995), 5080–5081.
45. Simpson, S.J., Shah, S., Comiskey, M., de Jong, Y.P., Wang, B., Mizoguchi, E., Bhan, A.K., Terhorst, C., T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J. Exp. Med. 187 (1998), 1225–1234.
46. Singh, U.P., Venkataraman, C., Singh, R., Lillard, J.W. Jr., CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication. Endocr. Metab. Immune Disord. Drug Targets 7 (2007), 111–123.
47. Strober, W., The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. Immunity 31 (2009), 377–388.
48. Strober, W., Inside the microbial and immune labyrinth: gut microbes: friends or fiends?. Nat. Med. 16 (2010), 1195–1197.
49. Strober, W., Fuss, I.J., Blumberg, R.S., The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20 (2002), 495–549.
50. Tamboli, C.P., Neut, C., Desreumaux, P., Colombel, J.F., Dysbiosis in inflammatory bowel disease. Gut 53 (2004), 1–4.
51. Trinchieri, G., Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3 (2003), 133–146.
52. Turner, J.R., Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9 (2009), 799–809.
53. Uhlig, H.H., Powrie, F., Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease. Eur. J. Immunol. 39 (2009), 2021–2026.
54. Uhlig, H.H., McKenzie, B.S., Hue, S., Thompson, C., Joyce-Shaikh, B., Stepankova, R., Robinson, N., Buonocore, S., Tlaskalova-Hogenova, H., Cua, D.J., Powrie, F., Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25 (2006), 309–318.
55. Vlantis, K., Polykratis, A., Welz, P.S., van Loo, G., Pasparakis, M., Wullaert, A., TLR-independent anti-inflammatory function of intestinal epithelial TRAF6 signalling prevents DSS-induced colitis in mice. Gut 65 (2016), 935–943.
56. Vlantis, K., Wullaert, A., Polykratis, A., Kondylis, V., Dannappel, M., Schwarzer, R., Welz, P., Corona, T., Walczak, H., Weih, F., et al. NEMO prevents RIP kinase 1-mediated epithelial cell death and chronic intestinal inflammation by NF-κB-dependent and -independent functions. Immunity 44 (2016), 553–567.
57. Wagle, P., Nikolić, M., Frommolt, P., QuickNGS elevates next-generation sequencing data analysis to a new level of automation. BMC Genomics, 16, 2015, 487.
58. Wymore Brand, M., Wannemuehler, M.J., Phillips, G.J., Proctor, A., Overstreet, A.M., Jergens, A.E., Orcutt, R.P., Fox, J.G., The altered schaedler flora: continued applications of a defined murine microbial community. ILAR J. 56 (2015), 169–178.
59. Xavier, R.J., Podolsky, D.K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007), 427–434.
60. Yen, D., Cheung, J., Scheerens, H., Poulet, F., McClanahan, T., McKenzie, B., Kleinschek, M.A., Owyang, A., Mattson, J., Blumenschein, W., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116 (2006), 1310–1316.
61. Zorzi, F., Monteleone, I., Sarra, M., Calabrese, E., Marafini, I., Cretella, M., Sedda, S., Biancone, L., Pallone, F., Monteleone, G., Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS ONE, 8, 2013, e54562.